GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (NAS:ASMB) » Definitions » Cyclically Adjusted Price-to-FCF

Assembly Biosciences (Assembly Biosciences) Cyclically Adjusted Price-to-FCF : (As of May. 19, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Assembly Biosciences Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Assembly Biosciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Assembly Biosciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences Cyclically Adjusted Price-to-FCF Chart

Assembly Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Assembly Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Assembly Biosciences's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Assembly Biosciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assembly Biosciences's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's Cyclically Adjusted Price-to-FCF falls into.



Assembly Biosciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Assembly Biosciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Assembly Biosciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-3.352/131.7762*131.7762
=-3.352

Current CPI (Mar. 2024) = 131.7762.

Assembly Biosciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -5.918 100.560 -7.755
201409 -5.642 100.428 -7.403
201412 -4.187 99.070 -5.569
201503 -3.979 99.621 -5.263
201506 -3.083 100.684 -4.035
201509 -3.616 100.392 -4.746
201512 -3.803 99.792 -5.022
201603 -6.420 100.470 -8.420
201606 -4.716 101.688 -6.111
201609 -5.503 101.861 -7.119
201612 -7.766 101.863 -10.047
201703 24.284 102.862 31.110
201706 -8.552 103.349 -10.904
201709 -7.573 104.136 -9.583
201712 -6.164 104.011 -7.809
201803 -9.216 105.290 -11.534
201806 -9.404 106.317 -11.656
201809 -8.066 106.507 -9.980
201812 -7.971 105.998 -9.910
201903 -11.887 107.251 -14.605
201906 -9.816 108.070 -11.969
201909 -8.613 108.329 -10.477
201912 -8.885 108.420 -10.799
202003 -8.650 108.902 -10.467
202006 -7.568 108.767 -9.169
202009 3.598 109.815 4.318
202012 -9.070 109.897 -10.876
202103 -11.014 111.754 -12.987
202106 -6.104 114.631 -7.017
202109 -4.973 115.734 -5.662
202112 -5.169 117.630 -5.791
202203 -6.858 121.301 -7.450
202206 -4.445 125.017 -4.685
202209 -4.910 125.227 -5.167
202212 -4.738 125.222 -4.986
202303 -5.511 127.348 -5.703
202306 -3.129 128.729 -3.203
202309 -3.162 129.860 -3.209
202312 13.838 129.419 14.090
202403 -3.352 131.776 -3.352

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Assembly Biosciences  (NAS:ASMB) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Assembly Biosciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Assembly Biosciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Assembly Biosciences (Assembly Biosciences) Business Description

Traded in Other Exchanges
Address
331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.
Executives
Alexander Schornstein 10 percent owner KAISER-FRIEDRICH-ALLEE 2, AACHEN 2M 52074
Nicole S White officer: Chief Manufacturing Officer C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD., FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
Gilead Sciences Inc 10 percent owner 333 LAKESIDE DR, FOSTER CITY CA 94404
Jason A Okazaki officer: Chief Legal & Business Officer C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
Delaney William E Iv officer: CSO, Virology C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
Jeanette M Bjorkquist officer: Principal Accounting Officer C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
John G Mchutchison director, officer: CEO and President 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Michael P. Samar officer: See Remarks C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST. SUITE 310, CARMEL IN 46032
Luisa M Stamm officer: Chief Medical Officer C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST, SUITE 310, CARMEL IN 46032
Michael Houghton director C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD., FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
Lisa Johnson-pratt director C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Jacqueline Sybil Papkoff officer: See remarks C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN STREET, SUITE 310, CARMEL IN 46032
Gina Consylman director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Richard James Colonno officer: Chief Science Officer ASSEMBLY BIOSCIENCES, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Thomas Joseph Russo officer: CFO C/O ASSEMBLY BIOSCIENCES, INC., 11711 N MERIDIAN ST, SUITE 310, CARMEL IN 46032

Assembly Biosciences (Assembly Biosciences) Headlines

From GuruFocus